Filing Flows › Vir Biotechnology (VIR) › Q4 2025 › vs Q3 2025
Vir Biotechnology (VIR) Q4 2025 vs Q3 2025 (quarter over quarter)
Vir Biotechnology's revenue rose $63.8M (267×) from $240K in Q3 2025 to $64.1M in Q4 2025.
Vir Biotechnology, Q4 2025: revenue $64.1M (+418% year over year), operating margin -74.8%, net loss $42.9M, operating cash flow −$25.9M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q4 2025 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $64.1M | $240K | $63.8M | 267× |
| Other income, net | $4.9M | $10.5M | −$5.6M | -54% |
| Income tax benefit | $137K | −$168K | $305K | — |
| Net loss | $42.9M | $163M | −$120M | -74% |
| Costs & expenses | $112M | $174M | −$61.9M | -36% |
| Operating costs | $112M | $174M | −$61.7M | -36% |
| Research & development | $88.3M | $151M | −$63.1M | -42% |
| SG&A | $23.6M | $22.2M | $1.4M | +6% |
| Operating cash sources | $42.9M | $163M | −$120M | -74% |
| Depreciation & amortization | $2.9M | $3.0M | −$100K | -3% |
| Share-based compensation | $11.2M | $11.4M | −$150K | -1% |
| Working capital & other | $2.9M | −$18.8M | $21.7M | — |
| Cash used in operations | $25.9M | $168M | −$142M | -85% |
| Net loss absorbed | $42.9M | $163M | −$120M | -74% |
Questions
How much did Vir Biotechnology's revenue grow quarter over quarter in Q4 2025?
Vir Biotechnology's revenue rose $63.8M (267×) from $240K in Q3 2025 to $64.1M in Q4 2025.